{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:06:03Z","timestamp":1788303963646,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC). This phase 1b\/2 study was designed to determine the recommended phase 2 dose (RP2D) of GT90001 plus nivolumab, and assess the safety and anti-tumor activity in patients with advanced HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with advanced HCC were recruited from 3 centers. Eligible patients in the dose de-escalation stage received the GT90001 on day 1 of a 14-day cycle in a rolling-six design with a fixed dose of nivolumab (3.0\u00a0mg\/kg). Patients in dose-expansion stage received the RP2D of GT90001 plus nivolumab. Primary endpoint was safety. Key secondary endpoint was objective response rate (ORR) as per RECIST 1.1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between July 9, 2019, and August 8, 2022, 20 patients were treated (6 in phase 1b; 14 in phase 2) and evaluable for analysis. In phase 1b, no dose-limiting toxicities were observed, and GT90001 7.0\u00a0mg\/kg was confirmed as the RP2D. Common grade 3\/4 adverse events (AEs) were platelet count decreased (15%). No deaths due to AEs were reported. Confirmed ORR and disease control rate were 30% (95% CI, 14.6%-51.9%) and 40% (95% CI, 21.9%-61.3%), respectively. Median duration of response was not calculated (95% CI, 7.39\u00a0months to not calculated). Median progression-free survival (PFS) was 2.81\u00a0months (95% CI, 1.71\u20139.33), with 6-month and 12-month PFS rates of 35% and 25%, respectively. One patient with multiple intra- and extra-hepatic metastases was diagnosed with pseudo-progression upon GT90001 plus nivolumab exposure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GT90001 plus nivolumab has a manageable safety profile and promising anti-tumor activity in patients with advanced HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier NCT03893695.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-023-03098-w","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:02:33Z","timestamp":1697760153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b\/2 study"],"prefix":"10.1186","volume":"21","author":[{"given":"Chiun","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Zhi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"issue":"4","key":"3098_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/JCRP.JCRP_21_21","volume":"8","author":"C Hsu","year":"2021","unstructured":"Hsu C. Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. J Cancer Res Pract. 2021;8(4):127\u201333.","journal-title":"J Cancer Res Pract"},{"issue":"10088","key":"3098_CR2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"3","key":"3098_CR3","first-page":"193","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind. Phase III Trial J Clin Oncol. 2020;38(3):193\u2013202.","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"4_suppl","key":"3098_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","volume":"40","author":"S Qin","year":"2022","unstructured":"Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B-Y, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40(4_suppl):383.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3098_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"7","key":"3098_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"26","key":"3098_CR7","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"3098_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2022.40.4_suppl.415","volume":"40","author":"C Yoo","year":"2022","unstructured":"Yoo C, Ryoo B-Y, Kim H-D, Ryu M-H, Kang B, Chon HJ, et al. Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE). J Clin Oncol. 2022;40(4_suppl):415.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3098_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3098_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","volume":"71","author":"DD Hu-Lowe","year":"2011","unstructured":"Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, et al. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 2011;71(4):1362\u201373.","journal-title":"Cancer Res"},{"issue":"4","key":"3098_CR11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1042\/BST20160093","volume":"44","author":"AG de Vinuesa","year":"2016","unstructured":"de Vinuesa AG, Bocci M, Pietras K, Ten Dijke P. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochem Soc Trans. 2016;44(4):1142\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"3098_CR12","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-13-2788","volume":"20","author":"RS Bhatt","year":"2014","unstructured":"Bhatt RS, Atkins MB. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res. 2014;20(11):2838\u201345.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3098_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","volume":"23","author":"BG Nixon","year":"2023","unstructured":"Nixon BG, Gao S, Wang X, Li MO. TGFbeta control of immune responses in cancer: a holistic immuno-oncology perspective. Nat Rev Immunol. 2023;23(6):346\u201362.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3098_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","volume":"7","author":"E Dodagatta-Marri","year":"2019","unstructured":"Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, et al. alpha-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFbeta antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer. 2019;7(1):62.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3098_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in tumor microenvironment dictate t helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179(5):1177-90 e13.","journal-title":"Cell"},{"issue":"9","key":"3098_CR16","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/1078-0432.CCR-15-1622","volume":"22","author":"LW Goff","year":"2016","unstructured":"Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, et al. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016;22(9):2146\u201354.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3098_CR17","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cam4.724","volume":"5","author":"T Doi","year":"2016","unstructured":"Doi T, Lee KH, Kim TM, Ohtsu A, Kim TY, Ikeda M, et al. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors. Cancer Med. 2016;5(7):1454\u201363.","journal-title":"Cancer Med"},{"issue":"9","key":"3098_CR18","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/annonc\/mdw240","volume":"27","author":"M Simonelli","year":"2016","unstructured":"Simonelli M, Zucali P, Santoro A, Thomas MB, de Braud FG, Borghaei H, et al. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Ann Oncol. 2016;27(9):1782\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"3098_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3098_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10637-014-0074-9","volume":"32","author":"A Necchi","year":"2014","unstructured":"Necchi A, Giannatempo P, Mariani L, Fare E, Raggi D, Pennati M, et al. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGFbeta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs. 2014;32(3):555\u201360.","journal-title":"Invest New Drugs"},{"issue":"11","key":"3098_CR21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.jtho.2016.06.024","volume":"11","author":"P Wheatley-Price","year":"2016","unstructured":"Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, et al. A phase II study of PF-03446962 in patients with advanced malignant pleural mesothelioma. CCTG trial IND.207. J Thorac Oncol. 2016;11(11):2018\u201321.","journal-title":"J Thorac Oncol"},{"issue":"20","key":"3098_CR22","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"8","key":"3098_CR23","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"7","key":"3098_CR24","first-page":"S808","volume":"33","author":"S Qin","year":"2022","unstructured":"Qin S, Chan S, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma. ESMO 2022. 2022;33(7):S808-69.","journal-title":"ESMO 2022"},{"issue":"8","key":"3098_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"issue":"suppl 7","key":"3098_CR26","first-page":"S808","volume":"33","author":"R Finn","year":"2022","unstructured":"Finn R, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO 2022. 2022;33(suppl 7):S808-69.","journal-title":"ESMO 2022"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03098-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03098-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:19:30Z","timestamp":1700295570000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03098-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3098"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03098-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice and was approved by the institutional review boards from all participating centers (Approval numbers: 201812030MSB, 19CT010Ae, AB-CR-108\u2013012). All patients signed written informed consent prior to any study-related procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}